| Literature DB >> 34894331 |
Vasiliki Papageorgiou1, Bethan Davies2, Emily Cooper3, Ariana Singer4, Helen Ward3.
Abstract
Despite developments in HIV treatment and care, disparities persist with some not fully benefiting from improvements in the HIV care continuum. We conducted a systematic review to explore associations between social determinants and HIV treatment outcomes (viral suppression and treatment adherence) in high-income countries. A random effects meta-analysis was performed where there were consistent measurements of exposures. We identified 83 observational studies eligible for inclusion. Social determinants linked to material deprivation were identified as education, employment, food security, housing, income, poverty/deprivation, socioeconomic status/position, and social class; however, their measurement and definition varied across studies. Our review suggests a social gradient of health persists in the HIV care continuum; people living with HIV who reported material deprivation were less likely to be virologically suppressed or adherent to antiretrovirals. Future research should use an ecosocial approach to explore these interactions across the lifecourse to help propose a causal pathway.Entities:
Keywords: Antiretroviral therapy; HIV; Meta-analysis; Social determinants of health; Socioeconomic factors; Systematic review; Viral suppression
Mesh:
Substances:
Year: 2021 PMID: 34894331 PMCID: PMC9046343 DOI: 10.1007/s10461-021-03551-y
Source DB: PubMed Journal: AIDS Behav ISSN: 1090-7165
Fig. 1PRISMA 2020 flow diagram.
Adapted from Page et al. [29]
Summary of key characteristics of included studies
| Characteristic | Total studies (%) |
|---|---|
| Publication type | |
| Peer-reviewed (e.g., journal article, short/brief report, short/concise communication) | 77 (92.8) |
| Not peer-reviewed (e.g., conference abstract, editorial letter, thesis) | 6 (7.2) |
| Setting | |
| North America | 61 (73.5) |
| Europe | 20 (24.1) |
| Asia | 1 (1.2) |
| Australia | 1 (1.2) |
| Study design | |
| Cohort/longitudinal | 31 (37.3) |
| Cross-sectionalb | 30 (36.1) |
| Otherc | 22 (26.5) |
| Social determinantsa | |
| Education | 52 (62.7) |
| Employment | 33 (39.8) |
| Food security | 7 (8.4) |
| Housing | 39 (47.0) |
| Income | 33 (39.8) |
| Poverty/deprivation | 9 (10.8) |
| Socioeconomic status/position | 4 (4.8) |
| Social class | 1 (1.2) |
| Primary outcome(s) | |
| Viral (non-)suppressiond | 38 (45.8) |
| Medication (non-)adherencee | 35 (42.2) |
| Both | 10 (12.0) |
| Secondary outcome(s)a | |
| Diagnosis-related | 1 (1.2) |
| Medication-related (e.g., initiation, use, coverage, response) | 8 (9.6) |
| HIV care-related (e.g., engagement, retention, missed visits) | 13 (15.7) |
aMore than 1 option possible
bIncludes cross-sectional surveys of cohort studies
cMixed methods (observational data extracted), programme evaluations, needs assessment, cross-sectional surveys/analysis of cohort studies and chart/record/baseline intervention reviews
dCD4 cell count, HIV viral load
eART, cART, HAART
Characteristics of included studies
| Population | Exposure | Outcomes | |||
|---|---|---|---|---|---|
| Study (publication type) | Setting (city/state, country) | Population of people living with HIV; project name (study design) | Social determinant(s)a | Virological (non-) suppression measureb | Medicationc (non-) adherence measure |
| North America (n = 61) | |||||
| Almeida-Brasil et al. 2018 [ | Canada | 566 adults with hepatitis C, receiving cART; part of Food Security & HIV-HCV Study (FS) of the Canadian Co-infection Cohort (CCC) (prospective cohort) | Education; employment; food security; income | VL > 50 copies/mL | Missed ≥ 1 cART dose, past 4 days |
| Anderson et al. 2018 [ | USA | 239 women at an urban HIV specialty clinic (cross-sectional) | Education; employment | CD4 < 200 cells/mm3 VL > 20 copies/mL | – |
| Baguso et al. 2019 [ | San Francisco (USA) | 123 self-identified transgender women; part of Transwomen Empowered to Advance Community Health 3 (TEACH 3) study (cross-sectional) | Education; housing | Detectable and unknown viral load | – |
| Berg et al. 2004 [ | Bronx, New York (USA) | 113 people who currently/formerly use opioids; part of HIV Epidemiologic Research on Outcomes (HERO) study (prospective cohort) | Housing | – | MEMS caps openings divided by number of prescribed doses |
| Blank et al. 2015 [ | Brooklyn; Chicago; Los Angeles; Miami; San Antonio; Longview; Anniston; and Chapel Hill (USA) | 944 women of colour; part of Special Projects of National Significance (SPNS) Enhancing Access to and Retention in Quality HIV Care for Women of Color initiative (prospective cohort) | Education; employment; housing | VL < 200 copies/mL | – |
| Chitsaz et al. 2013 [ | Connecticut; Georgia; Illinois; Massachusetts; New York; Ohio; Pennsylvania; Rhode Island; South Carolina (USA) | 1166 adults with a diagnosis of HIV before being jailed in 10 jails in US across 9 states; part of Enhance Link initiative (cross-sectional) | Education; employment; food security; housing | – | ≥ 95% ART adherence |
| Clemenzi-Allen et al. 2018 [ | San Francisco, USA | 1222 adults at HIV clinic (“Ward 86”) (cross-sectional) | Housing | VL < 200 copies/mL | – |
| Creasy et al. 2019 [ | Atlanta; Detroit; Houston; Memphis; Philadelphia; and Washington, DC (USA) | 5143 male and Black/African American adults recruited from Black Pride events; part of Promoting Our Worth, Equality, and Resilience (POWER) study (cross-sectional) | Housing | – | Missed doses (4–7/week, 2–3/week, 1/week, < 1/week, never) Last missed dose (never, ˃ 3 months,1–3 months, 3–4 weeks, 1–2 weeks, or within the week) |
| Doshi et al. 2017 [ | USA | 1,296,248 adults accessing ˃800 medical care providers, 2010–2014; part of Health Resources and Services Administration (HRSA) and served by Ryan White program (surveillance records review) | Housing | VL < 200 copies/mL | – |
| Dowshen et al. 2016 [ | USA (including Puerto Rico), 15 cities | 1584 “behaviourally-infected youth” (including 66 young transgender women) from a multisite study conducted at 20 Adolescent Medicine Trials Units; part of Adolescent Trials Network (ATN) (secondary data analysis—cross-sectional) | Housing | Detectable viral load | – |
| Fadul et al. 2017 [ | North Carolina, USA | 184 newly diagnosed people living with HIV treated in East Carolina University clinic; part of Ryan White program (retrospective chart review) | Education; housing; poverty | VL < 200 copies/mL | - |
| Feldman et al. 2015 [ | Greater New York metropolitan area (USA) | 2896 MSM; part of Ryan White Part A program (programme evaluation) | Education; housing | VL > 200 copies/mL CD4 < 350 cells/mm3 | – |
Feller and Agins 2016 [ (article) | New York State (USA) | 11,252 adults receiving treatment across 186 HIV clinics (classification and regression tree analysis algorithm—cohort) | Housing | VL < 200 copies/mL % virally suppressed | – |
| Gardner et al. 2015 [ | Ontario (Canada) | 3322 people living with HIV receiving clinical care; part of Ontario HIV Treatment Network Cohort Study (OCS) (cohort) | Income | VL < 200 copies/mL | – |
| Gebo et al. 2003 [ | USA | 196 people living with HIV taking at least 1 ART in an urban hospital clinic (John Hopkins University HIV Clinic) (cross-sectional) | Deprivation | – | < 90% ART adherence (stratified by injecting drug use and gender) |
| Golin et al. 2002 [ | Southern California (USA) | 117 people living with HIV in a county hospital HIV clinic with newly initiated HAART; part of Adherence and Efficacy to Protease inhibitor Therapy (ADEPT) study (prospective cohort) | Education; employment; income | – | Number of PI/NNRTI/HAART doses taken divided by prescribed over 4-weeks |
| Haider et al. 2019 [ | South Carolina (USA) | 342 people living with HIV receiving HIV care in immunology centre; part of Ryan White Program (cross-sectional) | Education; employment; income | VL < 100 copies/mL | – |
| Hussen et al. 2018 [ | Southeastern city, USA | 81 young Black gay, bisexual and other MSM aged 18–24 years old in a paediatric/adolescent clinic (cross-sectional) | Education; employment; housing | VL ≤ 40 copies/mL | – |
| Iralu et al. 2010 [ | Navajo Nation (USA) | 36 American Indians under Navajo AIDS Network (NAN) case management; part of Four Corners American Indian Circle of Services Collaborative (4CC) (cross-sectional) | Education; employment; housing; income | CD4 < 200 cells/mm3 Viral load (log) | – |
| Johnson et al. 2003 [ | San Francisco; Los Angeles; New York City; Milwaukee, (USA) | 2765 adults taking ART; part of Healthy Living Project (baseline pre-intervention—cross-sectional) | Education; employment; housing | – | 90% ART adherence, past 3 days |
| Kacanek et al. 2019 [ | USA (including Puerto Rico) | 122 18–22-year olds based across 15 clinical sites; part of Pediatric HIV/AIDS Cohort Study (longitudinal) | Income | VL > 400 copies/mL | Self-reported missed ≥ 1 ART dose, past week |
| Kalichman and Grebler 2010 [ | Atlanta, Georgia (USA) | 188 people living with HIV/AIDS who demonstrated poor health literacy (cross-sectional) | Education; employment; income; poverty | – | 85% ART adherence 75% ART adherence |
| Kalichman et al. 2010 [ | Atlanta, Georgia (USA) | 344 people living with HIV/AIDS (cross-sectional) | Education; employment; food security; housing; income | Undetectable viral load Change in most recent viral load Change in most recent T cells Most recent CD4 cell count | 80% ART adherence 90% ART adherence Self-report adherence rating Unannounced pill count adherence |
| Kalichman et al. 2014 [ | Atlanta, Georgia (USA) | 364 men and 157 women living with HIV (cross-sectional) | Food security | CD4 < 500 Detectable viral load | 85% ART adherence |
| Keith McInnes et al. 2013 [ | Atlanta; Baltimore; Bronx; Brooklyn/Manhattan; Houston; Los Angeles; Pittsburgh; and Washington, DC (USA) | 1871 veterans living with HIV; part of Veterans Aging Cohort Study (VACS) and completed 5th follow-up survey in 2010–2011 (cross-sectional analysis of longitudinal cohort) | Education; employment; housing; income | – | ART adherence (1-MEDOUT ≥ 0.90) |
| Kleeberger et al. 2004 [ | USA | 597 men living with HIV reporting use of HAART; part of Multicenter AIDS Cohort Study (prospective cohort) | Education; income | – | Negative change (%): visit-pairs with 100% adherence Positive change (%): visit-pairs with < 100% adherence |
| Koehn et al. 2020 [ | Vancouver (Canada) | 99 Dr Peter Centre clients who completed a 12-month follow-up interview (longitudinal cohort) | Education; employment; food security; housing; income | – | ≥ 95% cART adherence |
| Kyser et al. 2011 [ | Denver; Minneapolis; Providence; and St. Louis (USA) | 528 people living with HIV taking cART; part of study to understand the natural history of HIV/AIDS in the era of effective therapy (SUN) (cross-sectional analysis of longitudinal, prospective cohort) | Education; employment | – | cART adherence, past 3 days (missed ≥ 1 ART doses) |
| Lacombe-Duncan et al. 2019 [ | British Columbia, Ontario, and Quebec (Canada) | 50 transgender women; part of Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS) (cross-sectional / mixed methods) | Education; housing; income | VL < 50 copies/mL | ≥ 95% ART adherence |
| Lim et al. 2015 [ | New York City (USA) | 1698 people living with HIV /AIDS with both jail incarceration and homelessness (retrospective cohort) | Housing | VL < 400 copies/mL | – |
| Ludema et al. 2016 [ | Bronx; Brooklyn; Washington DC; Los Angeles; San Francisco; Chicago (USA) | 1481 women; part of Women’s Interagency HIV Study (WIHS) (prospective cohort) | Income | VL > 200 copies/mL | – |
| Marshall et al. 2016 [ | Vancouver (Canada) | 706 people who use drugs; part of AIDS Care Cohort to Evaluate Exposure to Survival Services (ACCESS) (prospective cohort) | Education; employment; housing | Undetectable VL or VL < 50 copies/mL | – |
| McCoy et al. 2016 [ | Arizona, California, Illinois, Massachusetts, Michigan, Pennsylvania, Texas, Washington, and Wisconsin (USA) | 426 people living with HIV aged 50 years and older; part of PRIME baseline study (baseline pre-intervention—cross-sectional) | Education; employment; income | – | ≥ 95% ART adherence |
| Miller et al. 2006 [ | British Columbia (Canada) | 892 people living with HIV; part of HIV/AIDS Drug Treatment Program of the British Columbia Centre for Excellence in HIV/AIDS (programme evaluation) | Housing; income | VL < 500 copies/mL | – |
| Mimiaga et al. 2019 [ | Rhode Island (USA) | 296 adults; part of Ryan White Part B HRSA (needs assessment) | Education; employment; housing; income | Virological non-suppression | Sometimes/never take ART as prescribed, past 12 months |
| Mohammed et al. 2004 [ | Louisiana (USA) | 273 adults from 8 areas in non-urban Louisiana (cross-sectional) | Education; employment | – | Self-report missed any HAART doses, previous week |
| Moore et al. 2016 [ | Vancouver (Canada) | 719 MSM; part of Momentum Health study (cross-sectional) | Education; income | VL ≥ 200 copies/mL | – |
| Nyaku, Beer and Shu 2019 [ | USA (including Puerto Rico) | 18,423 adults who self-reported taking ART: part of Medical Monitoring Project (MMP) (secondary data analysis—surveillance records review from cross-sectional sample) | Education; housing; poverty | – | ART non-persistence |
| O'Neil et al. 2012 [ | British Columbia (Canada) | 566 people living with HIV who have accessed ART; part of Longitudinal Investigations into Supportive and Ancillary health services (LISA) cohort study (cross-sectional analysis of cohort) | Education; housing; income | – | ≥ 95% HAART adherence |
| Oliver et al. 2019 [ | Nashville, Tennessee (USA) | 248 women living with HIV with ≥ 1 prenatal visit; part of Vanderbilt Obstetrics Comprehensive Care Clinic (VCCC) (observational cohort) | Education | VL ≥ 200 copies/mL | – |
| Phillips 2011 [ | USA | 160 Black men living with HIV/AIDS who use illicit drugs (cross-sectional) | Housing | – | Self-reported mean number of ART doses missed, past 4 days |
| Phillips et al. 2013 [ | Canada; USA (including Puerto Rico) | 1873 adults; part of International Nursing Network for HIV Research Study V (cross-sectional) | Education | – | ≥ 99% ART adherence (self-reported visual analogue scale for 30 days) |
| Rebeiro et al. 2018 [ | Southern USA | 2541 adults in viral suppression analysis; part of VCCC (observational cohort) | Socioeconomic status/position | VL < 200 copies/mL among those with ≥ 1 clinic visit | – |
| Robinson and Knowlton 2016 [ | Baltimore (USA) | 383 people who inject drugs formerly/currently (secondary data analysis—cross-sectional) | Education | VL ≤ 40 copies/mL | - |
| Santos et al. 2014 [ | San Francisco (USA) | 314 transgender women; part of San Francisco Transfemale Respondent Driven Sampling Study (secondary data analysis—cross-sectional) | Housing | VL ≤ 200 copies/mL | – |
| Sayles et al. 2012 [ | Los Angeles county (USA) | 11,397 people living with HIV who were uninsured; part of Ryan White program (cohort) | Housing; income | VL > 200 copies/mL | – |
| Schafer et al. 2012 [ | Virginia (USA) | 251 men and women; part of UVa Ryan White clinic (RWC) (cross-sectional cohort) | Education; socioeconomic status | CD4 < 200 Detectable HIV viral load | – |
| Shacham et al. 2010 [ | St Louis, Missouri (USA) | 514 people living with HIV presenting at Washington University HIV Clinic in 2007 (cross-sectional) | Education; employment; housing | VL ≥ 400 copies/mL | – |
| Shacham et al. 2013 [ | St Louis, Missouri (USA) | 762 people living with HIV presenting at Washington University HIV Clinic in 2008 (cross-sectional) | Employment; poverty | CD4 < 200 cells/μl VL < 400 copies/mL | – |
| Singh et al. 1999 [ | USA | 123 people who completed refill-methodology assessment of adherence (prospective cohort) | Education; employment; income | – | < 90% ART adherence |
| Stone et al. 2001 [ | Rhode Island; Maryland; New York State; Michigan (USA) | 289 women living with HIV/AIDS; part of HIV Epidemiologic Research (HER) longitudinal cohort study (cross-sectional survey of cohort) | Education | – | Missed ≥ 1 HAART doses, past 3 days |
| Storholm et al. 2019 [ | Los Angeles, California (USA) | 239 African American adults living with HIV recruited in community settings (246: Project Mednet and 108 from Project Rise) (longitudinal) | Education; employment; housing; income | – | ART adherence trajectory group: high-stable (mean > 90%), moderately low-stable (> 60%), low-decreasing (< 27%) at 2, 4, 6 months or 1.5, 4.5, 6 months |
| Sunil and McGehee 2007 [ | USA | 1910 people living with HIV taking ART; part of HIV Cost and Services Utilization Study (HCSUS) (cross-sectional survey of cohort) | Education | – | ART adherence, past 7 days (non-adherent: ≥ 1 medication missed) |
| Surratt et al. 2015 [ | Miami; Fort Lauderdale (USA) | 503 socioeconomically disadvantaged substance users (cross- sectional—structured interviews) | Housing; income; poverty | – | Missed ARTs because of diversion, past 90 days |
| Tymejczyk et al. 2018 [ | New York City (USA) | 1045 people living with HIV (sexual health clinic electronic medical records matched with longitudinal data from NYC HIV Surveillance Registry in 12 months before and after clinic visits) (secondary data analysis—linked surveillance and medical records review) | Poverty | VL ≤ 200 copies/mL | – |
| Vyas et al. 2014 [ | San Diego, California (USA) | 350 adults attending a HIV clinic (prospective longitudinal) | Income | – | ≥ 90% ART adherence |
| Wagoner et al. 2016 [ | Birmingham, Alabama (USA) | 382 people living with HIV at University of Alabama clinic (1917 Clinic) with a HIV viral load available; part of Project Client-Oriented New Patient Navigation to Encourage Connection to Treatment (CONNECT) (cohort) | Education | VL ≥ 200 copies/mL | – |
| Weiser et al. 2013 [ | San Francisco (USA) | 284 homeless and marginally housed individuals; part of San Francisco Research on Access to Care in the Homeless cohort (observational cohort) | Education; food security; housing; income | VL > 100 copies/mL CD4 < 200 cells/mm3 | < 90% ART adherence |
| Whelan et al. 2019 [ | King County, Washington (USA) | 549 newly diagnosed people living with HIV who received a partner services interview (retrospective cohort) | Housing | VL ≥ 200 copies/mL | – |
| Wilson et al. 2018 [ | San Francisco Bay Area (USA) | 159 transgender women of colour (55 participated at TransAccess, 46 at Brandy Martell Project, and 58 at Butterfly Project) as part of the Special Projects of National Significance (SPNS) Program, “Enhancing Engagement in Retention and Quality of Care for Transgender Women of Color” initiative (programme evaluation) | Food security; housing; income | CD4 < 500, past 6 months Undetectable VL, past 6 months | – |
| Yehia et al. 2014 [ | Philadelphia, Pennsylvania (USA) | 12,759 adults using multiple clinics for primary HIV care; part of Ryan White program (retrospective cohort) | Income | VL ≤ 200 copies/mL | – |
| Europe (n = 20) | |||||
| Abgrall et al. 2014 [ | France | 200 individuals from Sub-Saharan Africa adherent to cART at enrollment; part of Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS)-VIHVO study (cross-sectional) | Housing | – | < 80% cART adherence |
| Burch 2018 [ | UK | 2704 adults recruited from eight HIV outpatient clinics; part of Antiretrovirals Sexual Transmission Risk and Attitudes (ASTRA) study (cross-sectional) | Education; employment; housing; income | VL > 50 copies/mL VL > 200 copies/mL | ≥ 2 ART consecutive missed days, past 3 months or ≥ 1 missed, past 2 weeks |
| Carrieri et al. 2003 [ | Marseilles; Avignon; Nice; Paris suburbs (France) | 96 people who inject drugs (30 women, 66 men) living with HIV initially adherent to HAART in hospital clinics; part of French MANIF 2000 cohort (cohort) | Education; employment; housing | – | < 80% HAART adherence, past 18-months |
| Collazos et al. 2009 [ | Spain | 1352 people living with HIV from 69 hospitals; part of Grupo Español para el Estudio Multifactorial de la Adherencia (GEEMA) cohort (prospective cohort) | Education | CD4 + cell count (cells/µl) at baseline Undetectable VL (baseline and 12 months) VL (log copies/mL) at baseline | HAART adherence rates |
| D'Almeida et al. 2016 [ | France | 1246 people living with HIV who were HIV treatment-naïve at cART initiation and on cART for at least 12 months across 73 hospital departments; part of ANRS VESPA-2 study (cross-sectional) | Education; employment; deprivation | Sustained viral suppression (or undetectable VL < 50 copies/mL) for at least 6 months | – |
| Del Amo et al. 2017 [ | Austria, France, Germany, Greece, Italy, Spain, Switzerland, and the Netherlands | 24,069 people living with HIV with data on education from 15 cohorts of patients initiating cART; part of Collaboration of Observational HIV Epidemiological Europe (COHERE) within EuroCoord Network of Excellence (multi-site cohort) | Education | VL < 400 copies/mL (1 year after cART initiation) Immunological response (change in CD4 + count) at baseline, first 6 months and after 6 months | – |
| Dorz et al. 2003 [ | Italy | 88 male and 21 female adults living with HIV undergoing protease inhibitor treatment (cross-sectional) | Education; employment; income | – | < 80% adherence, past 7 days |
| Gordillo et al. 1999 [ | Madrid (Spain) | 366 people living with HIV on ART treatment (cross-sectional) | Education; employment | – | > 90% ART adherence ('good’) |
| Gueler et al. 2015 [ | Switzerland | 2694 ART-naïve for virologic response at six months; part of Swiss HIV Cohort Study (prospective cohort) | Socioeconomic position | Virological response to cART or viral suppression (VL < 50 copies/mL) at 6 months | – |
| Jansen et al. 2009 [ | Germany | 2045 people living with HIV; part of Competence Network for HIV/AIDS (KompNet) cohort (cohort) | Income | VL < detection limit CD4 + cell count | – |
| Papadopoulou 2000 [ | Enfield/Haringey, London (England) | 56 people living with HIV taking cART (cross-sectional) | Education | – | cART adherence (4 categories—“adhering to correct dose”, “taking drugs at right time”, “following dietary instructions” and “overall adherence”) |
| Parruti et al. 2006 [ | Abruzzo Region (Italy) | 171 people living with HIV clinically monitored for at least 24 weeks (cohort) | Employment; housing; SES | – | 90% HAART adherence |
| Persson et al. 1994 [ | Malmö (Sweden) | 47 MSM living with HIV (cross-sectional) | Social class | Low CD4 cell count (< median) | – |
| Raho-Moussa et al. 2019 [ | Paris (France) | 475 people living with HIV attending two hospital outpatient clinics on ART for at least 6 months (cross-sectional) | Education; employment; deprivation | VL > 50 copies/mL | – |
| Saracino et al. 2018 [ | Italy | 8023 ART naïve people living with HIV with Italian nationality; part of Italian Cohort Naïve Antiretrovirals (ICONA) cohort (observational cohort) | Education; employment | VL < 50 copies/mL | ART discontinuation |
| Sellier et al. 2006 [ | Paris (France) | 61 adults born in Sub-Saharan Africa and living in France attending 3 infectious diseases departments (cross-sectional) | Education; employment | – | Never missed ART doses compared to frequently or rarely |
Sherr et al. 2012 [ (article) | London (UK); South East (UK) | 259 adults living with HIV attending 5 HIV clinics (cross-sectional) | Education | – | All HAART doses taken at correct time and under correct conditions |
| Sobrino-Vegas et al. 2012 [ | Spain | 4549 people living with HIV from 27 public health centres; part of CoRIS (AIDS Research Network Cohort) (prospective cohort) | Education | Immunological response to treatment (CD4 + T-cell count) at 6 months and 1 year VL < 50 copies/mL (6 months and 1 year) | – |
| Spire et al. 2002 [ | France | 445 people living with HIV in 47 hospital departments; part of APROCO cohort (prospective cohort) | Housing; income | – | HAART non-adherence at 4 months follow up |
| Uusküla et al. 2012 [ | Kohtla-Järve (Estonia) | 144 people living with HIV receiving outpatient HIV care (cross-sectional) | Education; income | – | < 100% ART adherence |
| Asia and Australia (n = 2) | |||||
| Siefried et al. 2017 [ | Australia | 522 adults on ART at 7 clinics; part of Parameters Associated with Adherence to Antiretroviral Therapy (PAART) study (cross-sectional analysis of cohort) | Employment; housing; income | – | Self-reported missed ≥ 3 ART, past 3 months |
| Yang and Bang 2017 [ | South Korea | 300 people living with HIV from 6 hospitals; part of Nationwide Specialized Counseling Program (cross-sectional) | Education; employment; income | – | ≥ 95% ART adherence |
ART antiretroviral therapy, cART combination antiretroviral therapy, HAART highly active antiretroviral therapy, MEMS medication event monitoring system, MSM men who have sex with men, PI protease inhibitor, VL viral load
aMeasures of social determinants vary across studies and may be compared at individual, household, or neighbourhood level
bMeasures of viral suppression include CD4 cell count and viral load. cMedication includes ART, cART, and HAART
Fig. 2Forest plots of likelihood (aOR) of a virological suppression and b medication adherence among people living with HIV with low, compared to high, educational attainment after adjusting for sociodemographic factors. ART antiretroviral therapy, GED general educational diploma, VL viral load
Fig. 3Forest plots of likelihood (aOR) of a virological suppression and b medication adherence among people living with HIV with lower employment grade or unemployed status, compared to high, after adjusting for sociodemographic factors. VL viral load
Fig. 4Forest plots of likelihood (aOR) of a virological suppression and b medication adherence among people living with HIV living in unstable, compared to stable, housing after adjusting for sociodemographic factors. A meta-analysis is presented for virological suppression. M0 month 0, M4 month 4, SRO single room occupancy, VL viral load
Fig. 5Forest plots of likelihood (aOR) of a virological suppression and b medication adherence among people living with HIV who were disadvantaged, compared to more advantaged after adjusting for sociodemographic factors. EPICES Evaluation of Deprivation and Inequalities in Health Examination Centres, FPL federal poverty level, VL viral load